SCA
PBYI icon

Secor Capital Advisors’s Puma Biotechnology PBYI Stock Holding History

Secor Capital Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,548
Closed -$293K – 208
2019
Q1 		$293K Buy
+7,548
New +$231K 0.06% 332
2017
Q1 		– Sell
-17,765
Closed -$545K – 558
2016
Q4 		$545K Buy
+17,765
New +$768K 0.07% 334

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Secor Capital Advisors's PBYI Position: Q2 2019 in Review

Secor Capital Advisors sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 7,548 shares — an estimated $293K sold.

Secor Capital Advisors first reported a position in PBYI in Q4 2016 and held it in 2 quarters. The position peaked at $545K in Q4 2016. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Secor Capital Advisors reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 7,548 Puma Biotechnology shares in Q2 2019, an estimated $293K.
  • Secor Capital Advisors first reported a position in Puma Biotechnology in Q4 2016 and held it in 2 quarters.
  • Secor Capital Advisors's Puma Biotechnology position peaked at $545K in Q4 2016.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.